A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease

Ahmar U. Zaidi1, Alexander K. Glaros1,4, Soyon Lee2, Taiji Wang3*, Rhea Bhojwani3, Eric Morris3, Breanne Donohue2, Jincy Paulose2, Şerban R. Iorga2 and Dave Nellesen3

Abstract
Background and purpose: Sickle cell disease (SCD) is a collection of rare inherited blood disorders affecting approximately 100,000 people in the U.S. and 20–25 million people globally. Individuals with SCD experience recurrent episodes of severe and unpredictable pain that are caused by vaso-occlusive crises (VOCs), a hallmark of the disease. VOCs are the primary cause of hospitalization in SCD, result in missed workdays and school days, and decrease quality of life (QoL). Although VOCs cause significant burden in the lives of individuals with SCD, there is no synthesis on the frequency of VOCs in the real world. This systematic literature review sought to identify literature describing the frequency of VOCs experienced by individuals with SCD in real-world settings.

Methods: MEDLINE and 6 congresses were searched (date range: January 1, 2000 to June 30, 2020). Studies were reviewed independently by two researchers. Studies assessing frequency or prevalence of VOCs or VOC-related outcomes were included.

Results: Of 1438 studies identified in the search, 52 met pre-specified inclusion and exclusion criteria. Reported frequency of VOCs varied widely ranging from a mean or median of 0 VOCs/year to 18.2 VOCs/year. The proportion of patients experiencing ≥ 3 VOCs/year ranged from 4 to 67% and the proportion of patients experiencing ≥ 5 VOCs/year ranged from 18 to 59%. Measures of VOC severity were limited, with 13 studies considering frequency of complicated VOCs and only 1 study reporting duration of VOC episodes.

Conclusions: This is the first study to systematically assess published evidence pertaining to VOCs in real-world settings. Reported VOC frequency in real-world settings varied widely, with a majority of studies only considering VOCs managed in an inpatient or outpatient setting. Studies that considered VOCs managed at home reported a higher frequency of VOCs, suggesting that many studies may underestimate the frequency of VOCs. This systematic literature review (SLR) highlights the need for consistent reporting of (1) self-reported VOCs, including those managed at home, (2) definitions of VOCs, (3) complicated VOCs, and (4) duration of VOC episodes in literature.

Keywords: Vaso-occlusive crisis, Pain crisis, Sickle cell disease, Real-world, Incidence, Prevalence

Introduction
Sickle cell disease (SCD) is a collection of rare inherited blood disorders resulting from a mutation of hemoglobin that causes an abnormal sickling of red blood cells [1].

Approximately 100,000 people in the U.S. and 20–25 million people globally have SCD [2, 3]. Individuals with SCD have a reduced life expectancy and experience both acute and chronic complications. Sickled red blood cells, monocytes, platelets, and neutrophils tend to stick together, forming multicellular adhesion clusters in the bloodstream [4, 5]. These clusters impede regular blood flow and oxygenation, which can damage blood vessels and surrounding tissues via
ischemia reperfusion injury, leading to a number of acute and chronic complications [1, 6, 7]. A clinical hallmark of SCD is vaso-occlusive crisis (VOC), often characterized by the sudden onset of severe pain [8]. Though there are frequent and common sites of pain in patients with SCD, this pain can occur in virtually any part of the body, often with multiple locations affected simultaneously [7, 9]. VOCs are the primary cause of hospitalizations for patients with SCD and are associated with increased mortality and organ damage [6, 10]. However, due to barriers to accessing care, a large proportion (51–79%) of patients manage their VOCs at home [11, 12]. Increased frequency of VOCs is associated with a significant decrease in health-related quality of life (HRQoL) and is also associated with greater absenteeism and overall productivity loss [13, 14]. In addition, VOCs are also associated with the development of other complications including acute chest syndrome (ACS), priapism, and hepatic/splenic sequestration, which decrease HRQoL and require extensive healthcare resource utilization [6, 10].

The objective of this systematic literature review (SLR) is to summarize published literature describing the frequency of study-defined VOCs experienced by pediatric and adult patients with SCD as reported in real-world settings globally. Clinical trial data were not included as trial populations may not be representative of the patient population encountered in the real-world setting. Inclusion and exclusion criteria can modify the frequency of VOCs experienced in a trial. Therefore, real-world populations are more inclusive and more accurately represent the burden of VOCs. The following research questions were assessed in the real-world setting: (1) How are VOCs defined? (2) What is the annual frequency of VOCs? (3) What is the duration of a VOC? (4) How often are VOCs managed in different care settings?

**Methods**

**Literature search and screen**

MEDLINE, including MEDLINE In-Process, database was searched via Ovid (date range: January 1, 2000 to June 30, 2020). Additional manual searches of 6 relevant and publicly available congress abstract databases were conducted to capture recent research (last 2 years) which may not yet be indexed in MEDLINE. Complete search strategies are provided in Additional file 1.

All studies identified in the literature search were reviewed independently and in parallel by two researchers using an Excel-based screening platform. Any disagreements were resolved by discussion between researchers or by independent arbitration by a third researcher. Studies were first screened by title and abstract. The full-texts of studies that met inclusion criteria were then reviewed using the same inclusion and exclusion criteria. Studies were included if frequency or prevalence of VOCs or VOC-related outcomes were reported. VOC data reported at study baseline or in the absence of treatment was extracted in cases where multiple values for frequency or prevalence of VOCs or VOC-related outcomes were reported. No restrictions were placed on VOC definition; VOC definitions were extracted as reported in the study and included as available.

Evidence synthesis of frequency of VOCs was based on the number of VOCs experienced by the population during a specific time period. Evidence synthesis of prevalence of VOCs was based on the proportion of the population that experiences at least 1 VOC at or during a specific time period. The time period over which VOCs were reported varied, we converted to annual frequency rates. Evidence synthesis of frequency of complicated VOCs included VOCs with concomitant ACS, priapism, and hepatic/splenic sequestration. Due to statistical and methodologic heterogeneity among studies, we did not carry out statistical pooling.

Clinical trials and retrospective analyses of clinical trials were excluded. Inclusion and exclusion criteria for both database and additional supplementary manual searches of congresses are provided in Additional file 2.

**Data extraction**

Predefined variables were extracted from eligible studies by a single researcher and checked for accuracy by a second researcher. Extracted data included publication details, study methodology (e.g., design, number of patients), patient characteristics (e.g., age, race/ethnicity), and clinical outcomes (e.g., definition of VOC, annual frequency of VOCs, frequency of complicated VOCs).

Studies that reported timing of VOCs or VOC-related outcomes were extracted and included in the data analysis. Frequency of VOCs was extracted for the time-period reported in the study; the frequency was also annualized for comparability purposes between studies. Studies that did not report timing of VOCs or VOC-related outcomes were not extracted nor included in the data analysis and were tabulated in Additional file 3.

**Quality assessment**

Study quality assessment was conducted on all extracted studies using the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) questionnaire for prospective and retrospective observational studies [15]. Studies were assessed by a single researcher and checked for accuracy by a second researcher. The questionnaire has 12 questions, of which, 4 related to study “relevance” and 8 related to study “credibility,” which can be answered as “Y” (Yes), “N” (No), “NR” (Not Reported),
and “NA” (Not Applicable). The total number of affirmative responses to quality elements were tabulated for each study as the primary measure of study quality. In addition, the number of affirmative responses for study relevance-related and study credibility-related questions were separately tabulated for each study.

**Results**

**Study selection**

The initial search for studies yielded 1438 studies, of which 1408 were from an electronic database (date range: January 1, 2000 to June 30, 2020) and 30 were from manual searches of recent congresses (last 2 years). Title abstract screening excluded 1307 studies (outcome did not meet inclusion criteria \([n = 690]\); study type did not meet inclusion criteria \([n = 470]\); population did not meet inclusion criteria \([n = 80]\); animal study \([n = 34]\); duplicate \([n = 30]\); earlier publication of the same patient population \([n = 3]\)), leaving 131 full-text articles to be screened for final inclusion in the SLR. Of those, 36 were excluded after full-text screening (outcome did not meet inclusion criteria \([n = 25]\); study type did not meet inclusion criteria \([n = 7]\); non-English \([n = 2]\); population did not meet inclusion criteria \([n = 1]\); not legible \([n = 1]\)) leaving a final set of 95 for inclusion in the SLR (Fig. 1). Of the 95 studies included in the SLR, 52 studies reported timing of VOCs and VOC-related outcomes were extracted and included in the data analysis. A full list of included publications is provided in Additional file 4.

Figure 1 shows a PRISMA flow diagram summarizing the literature search process and exclusion counts by pre-specified inclusion/exclusion criteria.

**Study characteristics**

The analysis was based on 52 studies, representing a mix of retrospective observational (23 studies), prospective observational (21 studies), and cross-sectional (8 studies). This includes studies from the U.S. (19), Asia (10), Europe (9), Caribbean/South American (6), and Africa (3); as well as 5 studies comprising multiple countries.

Sample sizes varied widely across the 52 studies from a minimum of 15 patients to a maximum of 44,033. The mean sample size was 2794, median was 254, and the standard deviation was 7923. Of the 6 studies with sample sizes larger than 5000, 4 were analyses of administrative healthcare claims and 2 were analyses of electronic health records.

Patient demographics included a mix between pediatric-only (< 18 years; 15 studies), adult-only (≥ 18 years; 14 studies), and mixed pediatric and adult (23 studies). The availability of treatment information varied widely across the 52 studies. More than a third of studies did not report type of treatment received for SCD (18 studies). Among the studies that did report type of treatment
received for SCD. 12 studies reported hydroxyurea use only (proportion of patients treated with hydroxyurea ranged from 2 to 100% among these studies), 12 studies reported multiple treatments including hydroxyurea, and 10 studies reported some other form of treatment information. Additional treatment information can be found in Additional file 5.

**Clinical outcomes**

Thirty-nine studies reported VOC frequency or prevalence outcomes, of which 33 reported frequency of VOC and 25 reported prevalence of VOC. Among studies that reported prevalence of VOC, 11 reported the prevalence distribution.

Overall there is variability in the definition of VOC in literature. Among the 39 studies that reported VOC frequency or prevalence outcomes, the variable VOC definition in 15 studies required a healthcare visit (outpatient [OP], inpatient [IP], and/or emergency department [ED]); in 11, a hospitalization event; in 4, a healthcare visit documented by a medical claim; and in 5, considered self-reported VOCs, including VOCs that were managed at home. Four studies did not report how VOCs were defined within the study. A full list of definitions of VOCs, as reported by the original study authors, is provided in Additional file 4.

Reported mean or median VOC frequency varied widely in literature with a minimum of 0 VOCs/year [16] to a maximum of 18.2 VOCs/year [17]. Studies reporting higher frequencies of VOCs/year include a mixture of pediatric and adult patient populations, study countries, patient population size, and study type, as depicted in Fig. 2. The SLR identified 2 different patient cohorts across 4 publications which considered self-reported VOCs [18–21]. The first was the Sickle Cell World Assessment Survey (SWAY) of patients with SCD (≥ 16 years) from multiple countries across North and South America, Europe, and Africa [18, 19]. SWAY defined VOCs as severe patient-reported pain crises and reported a mean of 5.2 VOCs/year and a median of 3 VOCs/year. Among the 384 U.S. patients, a mean of 7.1 VOCs/year was reported [20]. The second was a prospective cohort study of 226 adult U.S. patients with SCD who completed daily pain diaries for up to 6 months [21]. In this study, VOCs were defined as consecutive days in which a patient reports pain, and means of 6.0 VOCs/6 months and 6.8 VOCs/6 months were reported among male and female patients, respectively. Key study characteristics of all studies that reported VOC frequency, ranked from lowest to highest reported VOC frequency, are provided in Table 1.

Prevalence of VOCs were reported in 10 studies, 4–67% of patients experienced ≥ 3 VOCs/year and 18.2–59% of patients experienced ≥ 5 VOCs/year. The 3 studies that considered self-reported VOCs were the upper range for both proportion of patients experiencing ≥ 3 VOCs/year and ≥ 5 VOCs/year [13, 19, 20]. However, 2 studies which considered VOCs managed in an OP, IP, or ED setting, but did not consider VOCs managed at home, reported a substantial proportion of patients (9.2–15.8%) who experienced a high number of VOCs (> 10 VOCs/year) [45, 49]. Key study characteristics of all studies that reported a VOC prevalence distribution are provided in Table 2. Only one study reported the duration of VOC episodes [39]. The analysis of claims data (N = 16,092) from the Truven Health MarketScan® Commercial Claims and Encounters Database (2000–2018) reported the mean duration of VOC episodes varied by treatment setting: inpatient (11.7 days), emergency room (2.3 days), and outpatient (1.9 days).

**Complicated VOCs**

Complicated VOCs include ACS, priapism, and hepatic/splenic sequestration. Only 13 unique studies reported frequency of complicated VOC: ACS (11 studies), hepatic/splenic sequestration (4 studies). No studies reported the frequency of priapism. Frequency of complicated VOC was < 1/year.

**Quality assessment metrics**

Study quality was assessed for all 52 extracted studies. The number of affirmative responses to quality elements were tabulated for each study to determine study quality. Among the assessed studies, the mean number of affirmative responses to quality elements was 7.25 (median = 7), out of a total possible score of 12. Fourteen of the 52 extracted studies were conference abstracts which provided less information and a lower mean average score 6.2 (median = 6), out of a total possible score of 12. All studies had a similar high scoring for study relevance (2–3, out of a total possible score of 4) but there was more variability in scoring credibility (2–6, out of a total possible score of 8). No association was detected between the quality scoring of a study and rate of reported VOCs (correlation coefficient = 0.2).

**Discussion**

The aim of this SLR was to assess published studies reporting the frequency of VOCs experienced by pediatric and adult patients with SCD as reported in real-world settings. Real-world studies have more inclusive patient populations and the potential to more accurately and completely capture the burden of VOCs and represent wider populations.

Definitions of VOCs, where present, differed across real-world studies with few commonalities except the
Fig. 2  Reported frequency of VOCs by study design, patient age group, and sample size. The vertical axis represents the reported frequency of VOCs in the real world. The horizontal axis represents the study design type. The color of the circular data point represents the age group of the patient population. The size of the circular data point represents the patient population size. Median age is reported where indicated (*), otherwise mean age is reported.
| Study identifier | Country       | N   | Mean age | VOC definition                                      | # of reported VOCs/year |
|------------------|---------------|-----|----------|----------------------------------------------------|-------------------------|
|                  |               |     |          |                                                    |                         |
|                  |               |     |          | Mean   | SD     | Range | IQR |
| Le et al. [16]   | Belgium       | 139 | 21       | Hospitalization                                   | 0/100 PY<sup>1a,b</sup> | –     | –    | –   |
|                  |               |     |          |                                                   | 29.6/100 PY<sup>1c</sup> | –     | –    | –   |
| Donaldson et al. [22] | Jamaica | 50  | 18.5     | NR                                                | 5.63/100 PY<sup>1d</sup> | –     | –    | –   |
| Upadhye et al. [23] | India    | 75  | NR       | NR                                                | 9.7/100 PY              | –     | –    | –   |
| Lamarre et al. [24] | French West Indies | 49 | 11.9     | Hospitalization                                   | 0.26<sup>1g</sup>      | 0.39  | –    | –   |
|                  |               | 44  | 11.4     |                                                    | 0.41<sup>f</sup>        |       |      |     |
| Willen et al. [25] | Multiple    | 165 | 10       | Hospitalization                                   | 0.27<sup>a</sup>        | –     | –    | –   |
| Asnani et al. [26] | Jamaica    | 850 | NR       | Healthcare visit (OP or IP) to center; recorded in database | 0.4                    | 0.7   | –    | –   |
| DeBaun et al. [27] | U.S        | 159 | 9<sup>a</sup> | Hospitalization and treatment with opioids         | 0.46<sup>a</sup>        | –     | –    | –   |
| Boyd et al. [28]  | U.S         | 242 | 0.25     | Healthcare visit (OP or IP) to clinic              | 0.47<sup>g</sup>        | –     | –    | –   |
| Rezende et al. [29] | Brazil    | 461 | 9.2      | Healthcare visit (OP or IP) to center              | 5/100 PY               | –     | 48.9–53.4 | –   |
| Schuchard et al. [30] | U.S     | 35  | 0.6      | Healthcare visit (OP or IP) to center              | 0.15<sup>h</sup>        | –     | –    | –   |
|                  |               | 13  | 1.6      |                                                    | 0.9                    | –     | –    | –   |
|                  |               | 17  | 3.0      |                                                    | 0.52<sup>j</sup>        | –     | –    | –   |
| Ceglie et al. [31] | Italy      | 16  | 10.5     | Hospitalization at study center                    | 0.6<sup>d</sup>         | –     | –    | –   |
|                  |               | 23  | 10.3     |                                                    | 1.6<sup>d</sup>         | –     | –    | –   |
| Inati et al. [32] | Lebanon      | 335 | 8.6      | Hospitalization                                   | 0.6                    | 0.6   | 0.04–2.4 | –   |
| Jain et al. [33]  | India        | 833 | NR       | Healthcare visit (OP or IP) to center              | 64/100 PY              | –     | –    | –   |
| Lettre et al. [34] | Multiple    | 1275| 14.5     | NR                                                | 0.7/PY              | –     | 1.4  | –   |
| Nimgaonkar et al. [35] | India    | 137 | 14<sup>a</sup> | NR                                              | 0.7                    | –     | –    | –   |
| Barner et al. [36] | U.S         | 1190| NR       | Healthcare visit (OP, IP, or ED)                   | 4.1/5 year study period | 5     | –    | –   |
| Willen et al. [37] | U.S         | 197 | 11       | Hospitalization and treatment with opioids         | 0.86                   | –     | –    | –   |
| Yates et al. [38]  | Multiple     | 15  | 9.6<sup>a</sup> | Hospitalization                                   | 1.18<sup>n</sup>      | –     | 0–1.94 | –   |
| Joseph et al. [39] | U.S         | 16,092| 36.7   | Healthcare visit (OP, IP, or ED); Texas Medicaid claims | 1.2                  | –     | –    | –   |
| Leleu et al. [40]  | France       | 157 | 33<sup>a</sup> | Healthcare visit (OP, IP, or ED); French National Health Data System | 1.9<sup>i</sup>     | –     | –    | –   |
| Janecek et al. [41] | U.S        | 66  | 38.8     | Healthcare visit (OP, IP, or ED)                   | 2<sup>o</sup>           | –     | –    | –   |
| Dave et al. [42]  | India        | 404 | 19       | Healthcare visit (OP or IP) to care system         | 2.77                   | –     | –    | –   |
| Madu et al. [43]  | Nigeria      | 126 | 24.9     | Healthcare visit (OP or IP) to center              | 3                      | 4.8   | –    | –   |
| Osunkwo et al. [18] | Multiple | 2145| NR       | Self-reported (patient survey; hospitalization, ED, managed at home) | 3<sup>a</sup>         | –     | 2–6  | –   |
| Latremouille-Viau et al. [44] | U.S     | 18,287| 28.5 | Healthcare visit (OP, IP, or ED); Medicaid and Medicare claims | 3.1<sup>q</sup>     | –     | –    | –   |
| Shah et al. [45]  | U.S         | 8521| 32.9     | Healthcare visit (OP, IP, or ED); Medicaid claims  | 3.31                   | –     | –    | –   |
| Desai et al. [46]  | U.S         | 44,033| 15.7 | Healthcare visit (≥ 2 OP, or ≥ 1 IP, or ED); Medicaid claims | 3.71                   | –     | –    | –   |
| James et al. [19] | Multiple     | 1513| 24.1     | Self-reported (patient survey; hospitalization, ED, managed at home) | 5.2                  | –     | –    | –   |
inclusion of “pain” or “crisis”. There was also no consensus in the specificity of definition (e.g., a “composite of pain” versus “pain in the extremities, back, abdomen, chest, or head for which no explanation other than SCA could be found, lasting at least 2 h, leading to a clinic visit, and which was not classified as one of the following: skeletal/joint events, ACS, right upper quadrant pain, dactylitis, neurologic events, anemic episodes, febrile illness, and priapism”). Furthermore, explicit exclusions of certain symptoms within some definitions (e.g., “headaches”, “pain […] which was not classified as one of the following: skeletal/joint events, ACS, right upper quadrant pain, dactylitis, neurologic events, anemic episodes, febrile illness, and priapism”) further complicate the conceptual framework for VOC.

Operationalization of VOCs differed as well. Reported mean or median VOC frequency varied widely in literature with a minimum of 0 VOCs/year [16] to a maximum of 18.2 VOCs/year [17]. Overall, this SLR identified 95 studies, 39 of which reported frequency of VOCs and 13 of which reported frequency of complicated VOCs. Almost half of studies (43 out of 95) that reported VOC outcomes did not report a time period for the VOC outcomes. These studies are presented in the Appendix but were not included for data analysis as the number of VOCs is not interpretable without a time period. Among the 52 studies included for data analysis, 14 were conference abstracts which had sparse information on study methodology, including VOC definition. Congress abstracts were included in this SLR to supplement the limited peer-reviewed literature base. Studies included in the analysis were a mix of retrospective observational, prospective observational, and cross-sectional study designs.

The majority of studies identified in this SLR only considered VOCs managed in an inpatient or outpatient setting. Other evidence suggest that the frequency of VOCs is likely to be undercounted, as a large proportion (51–79%) of individuals with SCD report treating VOCs at home [11, 12]. Additionally, many patients

Table 1 (continued)

| Study identifier          | Country         | N   | Mean age | VOC definition                                                                 | # of reported VOCs/year | Mean | SD  | Range | IQR |
|--------------------------|-----------------|-----|----------|--------------------------------------------------------------------------------|-------------------------|------|-----|-------|-----|
| Alsultan et al. [47]     | Saudi Arabia    | 159 | 17.8     | Hospitalization for > 48 h                                                    | 5.6                     | 5.7  | -   | 0–36  | -   |
| Andemariam et al. [20]   | U.S             | 384 | 30.1     | Self-reported (patient survey; hospitalization, ED, managed at home)           | 7.1                     | 5.7  | -   | -     | -   |
| Bronte-Hall et al. [48]  | U.S             | 149 | 33.2     | Healthcare visit (OP or IP to center)                                         | 10.4                    | -    | -   | -     | -   |
| McClish et al. [21]      | U.S             | 87  | 33.6     | Self-reported (patient diary)                                                 | 6.0/6 months           | 6.8/6 months | - | -   |
| Shome et al. [17]        | Bahrain         | 51  | 29.6     | Healthcare visit (OP or IP to center)                                         | 18.2                    | 17.5 | -   | -     | -   |

ED emergency department, IP inpatient, IQR interquartile range, NR not reported, OP outpatient, PY patient-year, SCD sickle cell disease, SD standard deviation, VOC vaso-occlusive crisis

* Median reported
* Adults study arm
* Adolescents study arm
* Cases arm, patients with steady-state HBF levels below 1%
* HbSC study arm
* HbSS study arm
* Non-asthmatic study arm
* Patients who started hydroxyurea between 5 months and 1 year of age
* Patients who started hydroxyurea between 1 and 2 years of age
* Patients who started hydroxyurea between 2 and 5 years of age
* Male study arm
* Female study arm
* Pre-hydroxyurea therapy study arm
* Patients who had at least 2 inpatient stays for SCD diagnosis/chronic long-term SCD, or a reimbursement for Siklos/Hydrea
* Pre-assessment study arm
* Medicaid claims study arm
* Medicare claims study arm
### Table 2  VOC prevalence distribution studies

| Study identifier  | Country | N   | Mean age | VOC definition                                      | Distribution of VOC, % |
|-------------------|---------|-----|----------|----------------------------------------------------|------------------------|
| Adekile et al.    | Kuwait  | 396 | 19.2     | Hospitalization                                    | 0/year: 3.3            |
|                   |         |     |          |                                                    | 1/year: 54.8           |
|                   |         |     |          |                                                    | 2–3/year: 13.2         |
|                   |         |     |          |                                                    | > 3/year: 18.9         |
| Aloni et al.      | Congo   | 168 | 10       | Hospitalization > 48 h                             | 0/year: 3.6            |
|                   |         |     |          |                                                    | 1–3/year: 51.8         |
|                   |         |     |          |                                                    | > 3/year: 44.6         |
| Andemariam et al. | U.S     | 384 | 30.1     | Self-reported (patient survey; hospitalization, ED, managed at home) | 0/year: 4              |
|                   |         |     |          |                                                    | 1–4/year: 38           |
|                   |         |     |          |                                                    | ≥ 5/year: 59           |
| Bailey et al.     | England | 15,076 | 30       | Healthcare visit (OP, IP, or ED)                   | ≥ 3/year: 4            |
| Dave et al.       | India   | 404 | 19       | Healthcare visit (OP or IP) to care system         | 0/year: 25.3           |
|                   |         |     |          |                                                    | 1–5/year: 50.6         |
|                   |         |     |          |                                                    | 5–10/year: 8.3         |
| Delicou et al.    | Greece  | 254 | NR       | Healthcare visit (OP, IP, or ED)                   | 1/year: 11.9           |
|                   |         |     |          |                                                    | 2/year: 15.6           |
|                   |         |     |          |                                                    | 2–3/year: 22.8         |
|                   |         |     |          |                                                    | ≥ 3/year: 49.8         |
| James et al.      | Multiple | 1513 | 24.1     | Self-reported (patient survey; hospitalization, ED, managed at home) | 0/year: 8              |
|                   |         |     |          |                                                    | 1–4/year: 51           |
|                   |         |     |          |                                                    | ≥ 5/year: 40           |
| Latremouille-Viau et al. | U.S | 18,287 | 28.5    | Healthcare visit (OP, IP, or ED); Medicaid and Medicare claims | 0/year: 36.1           |
|                   |         |     |          |                                                    | 1/year: 17             |
|                   |         |     |          |                                                    | ≥ 2/year: 46.8         |
|                   |         |     |          |                                                    | 0/year: 44.9           |
|                   |         |     |          |                                                    | 1/year: 11.4           |
|                   |         |     |          |                                                    | ≥ 2/year: 43.7         |
| Rizio et al.      | U.S     | 303 | 34.4     | Self-reported (ASCQ-Me)                            | 0/year: 8.9            |
|                   |         |     |          |                                                    | 1/year: 9.6            |
|                   |         |     |          |                                                    | 2/year: 14.5           |
|                   |         |     |          |                                                    | 3/year: 19.8           |
|                   |         |     |          |                                                    | ≥ 4/year: 47.2         |
| Shah et al.       | U.S     | 8521 | 32.9     | Healthcare visit (OP, IP, or ED); Medicaid claims | 0/year: 52.3           |
|                   |         |     |          |                                                    | 1/year: 14.7           |
|                   |         |     |          |                                                    | 2/year: 6.7            |
|                   |         |     |          |                                                    | 3/year: 4.6            |
|                   |         |     |          |                                                    | 4/year: 3.7            |
|                   |         |     |          |                                                    | 5/year: 2.7            |
|                   |         |     |          |                                                    | 6/year: 2              |
|                   |         |     |          |                                                    | 7/year: 1.5            |
|                   |         |     |          |                                                    | 8/year: 1.4            |
|                   |         |     |          |                                                    | 9/year: 1.4            |
|                   |         |     |          |                                                    | > 10/year: 9.2         |
| van Tuijn et al.  | Netherlands | 95  | 37       | Hospitalization                                   | 0/year: 23             |
|                   |         |     |          |                                                    | 0–1/year: 43           |
|                   |         |     |          |                                                    | > 1/year: 16           |
report experiencing at least one barrier to receiving SCD-related healthcare services, citing barriers such as discrimination by health professionals, limited SCD centers, and difficulty trusting healthcare professionals, which can also contribute to VOCs being undercounted [12]. Among those studies in this SLR that included self-reported VOCs or those managed in a home setting, the mean annualized frequency was generally higher, ranging from 5.2 to 13.6 VOCs/year [19–21]. This is also consistent with a recent prospective cohort study published after the search period for this SLR, in which 35 U.S. patients were followed for 6 months and reported a median annualized frequency of 8 VOCs/year, with a mean duration of 2.7 days and 62.3% of VOC events self-managed at home [50]. Patients self-reported VOCs in their daily pain diary that were managed at home, in a clinic, in the emergency department, or in the hospital. This higher annualized frequency, 8 VOCs/year, is consistent with the range of frequencies, 5.2–13.6 VOCs/year, reported in other studies we identified in the SLR which considered self-reported VOCs or those self-managed in a home setting [19–21].

Few studies reported measures of VOC severity including the frequency of complicated VOCs, such as ACS, priapism, and hepatic/splenic sequestration. Studies that did report complicated VOCs found a frequency of <1 per year. Only 1 study reported the duration of VOC episodes which ranged from 1.9 days (outpatient) to 11.7 days (inpatient) depending on treatment setting [39]. Given that many VOCs are managed at home, additional evidence is needed to assess the severity of VOCs. For example, it remains uncertain whether VOCs managed at home are actually less severe than those treated in an outpatient or inpatient setting, or merely under-reported. Furthermore, there is no well-accepted definition of overall SCD severity and VOC severity [51]. For this reason, some have advocated a shift away from the term VOC in favor of “acute pain episode”, which would likely reveal the incidence to be even greater, not only by eliminating the criterion for healthcare utilization, but also reducing the dependence on subjective scales of severity. Results from this SLR support the need for application of a consistent definition of VOCs in clinical research, as well as for consistent measurement and reporting of the complicated VOCs [52].

### Limitations

The findings in the current SLR are subject to several limitations. Literature reviews are inherently limited by the accuracy of search terms used, which, in part, reflects the consistency in nomenclature and language used to describe the condition. While every attempt was made to use broad and effective search terms, and database search was supplemented by manual searches, some relevant studies can still be missed. In the context of a review of studies reporting VOC frequency, aggregating or comparing results is limited by variation in study designs and VOC definition/measurement standards, such that results are not necessarily directly comparable given these methodological differences. Although ranges were provided, statistical analysis or comparisons may be misleading given this heterogeneity. The study was not designed to assess the effect on interventions on VOCs. The SLR did not analyze concomitant treatments such as hydroxyurea and the differences in VOC frequency based on concomitant treatments. Due to the broad range of study designs included in the SLR (cross-sectional surveys, prospective studies, retrospective studies), treatment information reported among the 52 studies was variable and often limited, with more than a third of studies not reporting any form of treatment information (18/52; 34.6%). In addition, when treatment information for SCD was reported, studies varied in when the treatment was received (e.g., at baseline, during the study period, during VOCs only) and the types of treatments received (e.g., hydroxyurea only, multiple treatments including hydroxyurea, transfusions). International variability in treatment availability and clinical guidelines also likely affected treatment choice among patients with SCD. Finally, this SLR excluded clinical trials in order to study the frequency of VOCs in the real world independent of any particular treatment. Future real-world evidence is likely to include recently approved interventions known to reduce VOC frequency, potentially enabling research to assess comparative effectiveness of various treatments that reduce the rate of VOCs in real-world populations.

### Table 2 (continued)

| ASCQ-Me | adult sickle cell quality of life measurement information system, ED emergency department, IP inpatient, NR not reported, OP outpatient, VOC vaso-occlusive crisis |
|---|---|
| a | Median reported |
| b | Medicaid claims study arm |
| c | Medicare claims study arm |
Conclusions
To the best of our knowledge, this study is the first to systematically assess and synthesize literature on the frequency of VOCs in SCD in real-world settings. The SLR identified a wide range of definition of VOC and frequency of VOC experienced in real-world settings, with a majority of studies considering VOCs managed in an inpatient or outpatient setting. However, VOCs are often self-managed in the home care setting, and, among studies that did assess VOCs managed at home, frequency of VOCs was found to be higher. Measures of VOC severity were limited, with few studies that measured complicated VOCs and only 1 study reporting the duration of a VOC episode. This SLR highlights the need for consistent reporting of (1) self-reported VOCs, including those managed at home, (2) definitions of VOCs, (3) complicated VOCs, and (4) duration of VOC episodes in literature. Such research will increase the understanding of the impact of VOCs on individuals with SCD and enable caregivers to more effectively manage this serious disease.

Abbreviations
ACS: Acute chest syndrome; ED: Emergency department; HRQoL: Health-related quality of life; IP: Inpatient; ISPOR: International society of pharmaco-economics and outcomes research; OI: Outpatient; QoL: Quality of life; SCD: Sickle cell disease; SLR: Systematic literature review; SWAY: Sickle cell world assessment survey; VOC: Vaso-occlusive crisis.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13023-021-02096-6.

Funding
This study was funded by Novartis Pharmaceuticals Corporation. The funder provided support in the form of salaries for authors SL, BD, JP, and SRI. The funder also provided consultation fees to Analysis Group Incorporation, employer of TW, RB, EM, and DN, which is a paid consultant in connection with this study and the development of this manuscript. All authors contributed to the development of the study protocol, analysis plan, and data interpretation, and to the preparation and review of the manuscript.

Availability of data and materials
Detailed search strategy, inclusion and exclusion criteria, and list of included studies can be found in the supplementary information available with the online version of this article. For all other original data, please contact taij.wang@analysisgroup.com.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
This study was funded by Novartis Pharmaceuticals Corporation. AUZ reports honoraria from Novartis, Global Blood Therapeutics, Emmaus Life Sciences, bluebird bio, Chiesi, and Cyclencon, speaker bureau for Global Blood Thera-peutics, and funding from Novartis and Emmaus Life Sciences. AKG has no conflicts of interest to disclose. TW, RB, EM, and DN are employees of Analysis Group, Inc., a company that received funding from Novartis Pharmaceuticals Corporation to conduct this study. SL, BD, JP, and SRI are full-time employees of Novartis Pharmaceuticals Corporation.

Author details
1. Children’s Hospital of Michigan, Detroit, MI, USA. 2. Novartis Pharmaceutical Corporation, East Hanover, NJ, USA. 3. Analysis Group, Inc., 1010 El Camino Real, Suite 310, Menlo Park, CA 94025, USA. 4. Central Michigan University, Mount Pleasant, MI, USA.

Received: 9 June 2021 Accepted: 24 October 2021 Published online: 02 November 2021

Acknowledgements
Not applicable.

Authors’ contributions
Analyses were carried out by TW, RB, EM, and DN. All authors participated in the conception and design of the study and the interpretation of data, and all approved the final manuscript for publication.

References
1. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10109):311–23. https://doi.org/10.1016/S0140-6736(17)30193-9.
2. Centers for Disease Control and Prevention. Sickle cell disease (SCD). 2019. [Cited 2020 September 20]. Available from: https://www.cdc.gov/nchddds/sicklecell/data.html.
3. American Society of Hematology. State of sickle cell disease: 2016 report. 2016.
4. Gutsaeva DR, Parkerson JR, Yerigenahally SD, Kurz JC, Schaub RG, Ikuta T, et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood. 2011;117(2):727–35. https://doi.org/10.1182/blood-2010-05-285718.
5. Sparkenbaugh E, Pawlinski R. Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol. 2013;162(1):3–14. https://doi.org/10.1111/bjh.12336.
6. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561–73. https://doi.org/10.1056/NEJMra1510865.
7. Kanter J, Kruse-Jarres R. Management of sickle cell disease from childhood through adulthood. Blood Rev. 2013;27(6):279–87. https://doi.org/10.1016/j.bler.2013.09.001.
8. Yawn BP, John-Sowah J. Management of sickle cell disease: recommendations from the 2014 expert panel report. Am Fam Physician. 2014;92(12):1069–76.
9. Brozović M, Davies SC, Brownell AI. Acute admissions of patients with sickle cell disease who live in Britain. BMJ (Clin Res ed). 1987;294(6581):1206–8.

10. Shah N, Bhor M, Xie L, Halloway R, Arcona S, Paulose J, et al. Evaluation of vaso-occlusive crises in United States sickle cell disease patients: a retrospective claims-based study. JHEOR. 2019;6(3):106–17.

11. Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Rahman B, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94–101.

12. Rizzo A, Lin X, McCausland K, White M, Bhor M, Paulose J, et al., editors. Patients experiencing with sickle cell disease: treatment patterns, management of vaso-occlusive crises, and barriers to care [abstract]. Presented at: 47th annual national convention of SCDAAD; Baltimore, MD; 2019.

13. Rizzo A, Bhor M, Lin X, McCausland KL, White MK, Paulose J, et al. The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease. Qual Life Res. 2020;29(6):1533–47. https://doi.org/10.1007/s11136-019-02412-5.

14. Bailey M, Abiyoue A, Morgan G, Burke T, Disher T, Brown S, et al., editors. A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value Health. 2014;17(2):143–56. https://doi.org/10.1016/j.vhealal.2013.12.011.

15. Le P, Gulbis B, Dedekian L, Rozen L, Verrylen C, Vanderfaellie A, et al., editors. Is there an increase in sickle cell related events among the adult Belgian population [abstract]? Presented at: 60th American society of hematology annual meeting and exposition; Orlando, FL, USA; 2019.

16. Berger ML, Martin BC, Husereau D, Worley K, Allen JD, Yang W, et al. Hydroxyurea treatment of children with hemoglobin SC disease. Pediatri Blood Cancer. 2016;73(1):101–11. https://doi.org/10.1002/pbc.31288-015-0529-9.

17. Shome DK, Al Ajmi A, Khare A, et al. Vaso-occlusive crises and costs of sickle cell disease from a country and age analysis of the international sickle cell world assessment survey (SWAY) [abstract]. Presented at: 26th congress of the European hematology association; virtual, 2020.

18. James J, Andemaram B, Inusa B, El-Rassi F, Francis-Gibson B, Néro A, et al., editors. Management strategies and satisfaction levels in patients with sickle cell disease: interim results from the international sickle cell world assessment survey (SWAY) [abstract]. Presented at: 61st American society of hematology annual meeting and exposition; Orlando, FL, USA; 2019.

19. Andemaram B, James J, Inusa B, El-Rassi F, Francis-Gibson B, Néro A, et al., editors. Management strategies and satisfaction levels in patients with sickle cell disease: interim results from the international sickle cell world assessment survey (SWAY) [abstract]. Presented at: The foundation for sickle cell disease research congress; virtual, 2020.

20. McClish DK, Levenson JL, Penberthy LT, Robe SD, Bovbjerg VE, Roberts JD, et al. Gender differences in pain and healthcare utilization for adult sickle cell patients: the PiSCES project. J Womens Health. 2006;15(2):146–54.

21. Donaldson A, Thomas P, Seijeant BE, Seijeant FR. Gastro haemoglobin in homzygous sickle cell disease: a study of patients with low HBF levels. Clin Lab Haematol. 2001;23(3):285–9.

22. Upadhye DS, Jain DL, Trivedi VL, Nadkarni AH, Ghosh K, Colah RB. Neutonal screening and the clinical outcome in children with sickle cell disease in Central India. PLoS ONE. 2016;11(1):e0147081. https://doi.org/10.1371/journal.pone.0147081.

23. Lamarré R, Romana M, Waltz X, Lalanne-Alstrin ML, Tressiers B, Divatle-Doudmo L, et al. Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease. Haematologica. 2012;97(11):1641–7. https://doi.org/10.3324/haematol.2012.066670.

24. Willen SM, Rodeghier M, Strunk RC, Bacharier LB, Rosen CL, Kirkham FJ, et al. Aeroallergen sensitization predicts acute chest syndrome in children with sickle cell anemia. Br J Haematol. 2018;180(4):571–7. https://doi.org/10.1111/bjh.15076.
laboratory associations. Med Princ Pract. 2014;23(3):259–63. https://doi.org/10.1159/000360608.
44. Latremouille-Viau D, Bhor M, Sharma V, Puckrein G, Gagnon-Sanschagrin P, Khare A, et al., editors. Vaso-occlusive crises and costs of sickle cell disease in medicaid and medicare beneficiaries: the perspective of public payers [abstract]. Academy of managed care pharmacy managed care and specialty pharmacy annual meeting; virtual; 2020.
45. Shah N, Bhor M, Xie L, Paulose J, Yuce H. Sickle cell disease complications: prevalence and resource utilization. PLoS ONE. 2019;14(7):e0214355. https://doi.org/10.1371/journal.pone.0214355.
46. Desai R, Mahesri M, Levin R, Globe D, McKenracher K, Mutebi A, et al., editors. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of medicaid beneficiaries [abstract]. Presented at: 61st American society of hematology annual meeting and exposition; Orlando, FL, USA; 2019.
47. Alsultan A, Alleem A, Ghabbour H, AlGahtani FH, Al-Shehr A, Osman ME, et al. Sickle cell disease subphenotypes in patients from Southwestern Province of Saudi Arabia. J Pediatr Hematol Oncol. 2012;34(2):79–84. https://doi.org/10.1097/MPH.0b013e3182422844.
48. Bronte-Hall L, Parkin M, Green C, Tchouambou D, Huynt H, Puri-Sharma C, et al., editors. Real-world clinical burden of sickle cell disease in the US community-practice setting: a single-center experience from the foundation for sickle cell disease research [abstract]. Presented at: 14th Annual sickle cell disease research and educational symposium; virtual; 2020.
49. Delicou S, Diamantidis M, Manganas K, Eftychiadis E, Pantelidou D, Kouraki A, et al., editors. Sickle-cell disease in Greece: patient reported outcomes related to clinical complications, treatment choices and attitudes, beliefs and trends affecting potential participation in clinical trials—a Greek national multicentric study [abstract]. Presented at: 61st American society of hematology annual meeting and exposition; Orlando, FL, USA; 2019.
50. Pittman D, Hines PC, Beidler DR, Rybin D, Frelinger AL, Michelson AD, et al. Evaluation of longitudinal pain study in sickle cell disease (ELIPSIS) by electronic patient-reported outcomes, actigraphy, and biomarkers. Blood. 2020. https://doi.org/10.1182/blood.2020006020.
51. Shah N, Beenhouwer D, Broder MS, Bronte-Hall L, De Castro LM, Gibbs SN, et al. Development of a severity classification system for sickle cell disease. Clin Econ Outcomes Res CER. 2020;12:625–33. https://doi.org/10.2147/ceor.S276121.
52. Darbani DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. Eur J Haematol. 2020;105(3):237–46. https://doi.org/10.1111/ejh.13430.
53. Adekile AD, Al-Sherida S, Marouf R, Mustafa N, Thomas D. The subphenotypes of sickle cell disease in Kuwait. Hemoglobin. 2019;43(2):83–7. https://doi.org/10.1080/03630269.2019.1610427.
54. Aloni MN, Nkoe L. Challenge of managing sickle cell disease in a pediatric population living in Kinshasa, Democratic Republic of Congo: a sickle cell center experience. Hemoglobin. 2014;38(3):196–200. https://doi.org/10.3109/03630269.2014.896810.
55. van Tuijn CFJ, Schimmel M, van Beers EJ, Nue E, Biemond BJ. Prospective evaluation of chronic organ damage in adult sickle cell patients: a seven-year follow-up study. Am J Hematol. 2017;92(10):ES84–90. https://doi.org/10.1002/ajh.24855.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.